SK Pharmteco to Invest $35 Million toward Site Expansion
CDMO’s Ireland campus will increase in capacity by 50% as a result
SK Pharmteco, a contract development and manufacturing organization (CDMO) that is part of SK Inc., will be investing $35 million for the initial phase of an expansion plan for SK Biotek Ireland’s Dublin-based pharmaceutical manufacturing plant. The project—the CDMO says—is anticipated to provide a major increase in site manufacturing capacity and capabilities for its global customer base.
The new building is expected to be completed by 2024.
Phase 1 of the project will feature a new manufacturing building, increasing reactor volume capacity by about 936 cubic feet. There will also be filtration and drying equipment, associated utilities, and the capability for additional manufacturing lines and technologies. The expansion project in its entirety will consist of two phases—additional funding will be named at a later date. On completion, the expansion will result in an overall 50% increase in capacity at the Swords (Dublin) campus.
“It is an exciting project for the business and for our customers," notes Martin O’Halloran, the company’s director of engineering. “It will bring additional manufacturing capacity and capability to deliver pharmaceutical products that meet our customer needs and provide benefits to many patients over the coming years.”
